yingweiwo

Ketorolac hemicalcium

Ketorolac (RS37619) hemicalcium is a non-steroidal anti~inflammatory agent and a non-selective COX inhibitor (antagonist) with IC50s of 20 nM and 120 nM for COX-1 and COX-2 respectively.
Ketorolac hemicalcium
Ketorolac hemicalcium Chemical Structure CAS No.: 167105-81-9
Product category: New3
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
50mg
Other Sizes

Other Forms of Ketorolac hemicalcium:

  • Ketorolac (RS37619)
  • (S)-Ketorolac [(-)-Ketorolac)]
  • (R)-Ketorolac [(+)-Ketorolac)]
  • Ketorolac D5
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Ketorolac (RS37619) hemicalcium is a non-steroidal anti~inflammatory agent and a non-selective COX inhibitor (antagonist) with IC50s of 20 nM and 120 nM for COX-1 and COX-2 respectively. Ketorolac tromethamine is used as 0.5% eye drops in studies of allergic conjunctivitis, cystic macular edema, intraoperative miosis, and postoperative ophthalmitis pain. Ketorolac hemicalium is also a DDX3 inhibitor and may be utilized in cancer-related research.
Ketorolac hemicalcium is the hemicalcium salt of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase-1 (COX-1) and COX-2. It inhibits COX-1 with an IC50 of 20 nM and COX-2 with an IC50 of 120 nM, blocking prostaglandin synthesis and producing analgesic, anti-inflammatory and antipyretic effects. Ketorolac is used for short-term management of moderate to severe pain, including postoperative pain, and is available orally and parenterally.
Biological Activity I Assay Protocols (From Reference)
Targets
COX-1 (IC50 = 20 nM); COX-2 (IC50 = 120 nM); prostaglandin synthesis; non-selective COX inhibitor.
ln Vitro
In 48 hours, ketorolac (RS37619) salt (0–30 μM) efficiently destroys oral cancer cells [4]. In H357 cells, ketorolat (0–5 μM; 48 h) causes apoptosis and suppresses the production of the DDX3 protein [4]. The growth of oral cancer cells is inhibited by ketorolat (0-2.5 μM; 0-16 hours) [4]. Ketorolat (0-50 μM) decreases ATPase activity by directly interacting with DDX3 [4].
Ketorolac hemicalcium non-selectively inhibits COX-1 (IC50 = 20 nM) and COX-2 (IC50 = 120 nM), showing approximately 6-fold preference for COX-1. It blocks arachidonic acid conversion to prostaglandin H2, reducing prostaglandin-mediated pain and inflammation. Its potent analgesic activity is comparable to opioids for moderate pain, but it carries class-related gastrointestinal and renal risks.
ln Vivo
Rabbits treated with ketorolac (RS37619) (0.4% Ketorolac Tromethamine Eye Drops) demonstrated strong ocular anti-inflammatory effects [1]. There are no negative effects of ketorolac (4 mg/kg/day orally; 2 weeks) on the volume fraction of trabecular bone formed in the rats' alveolar sockets [2]. In rats, intrathecal injection of ketorolac (60 μg) once reduces damage from spinal cord ischemia [3]. Oral cancer incidence in mice is decreased by ketorolat (20 and 30 mg/kg; intraperitoneal injection; twice weekly for 3 weeks) [4].
In vivo, ketorolac hemicalcium is orally and parenterally active and provides analgesia for moderate to severe pain. Typical adult doses are 10–30 mg intramuscularly or intravenously every 6 hours (maximum 120 mg/day) and 10 mg orally every 4–6 hours. It is used for postoperative pain and is not recommended for long-term use due to gastrointestinal and renal toxicity.
Enzyme Assay
For COX-1 and COX-2 assays, purified ovine COX-1 or human recombinant COX-2 is incubated with arachidonic acid and a chromogenic peroxidase substrate in the presence of serially diluted ketorolac hemicalcium (0.1 nM–10 μM). Enzyme activity is measured at 590 nm, and IC50 is derived for each isoform.
Cell Assay
Cell viability assay [4]
Cell Types: HOK, SCC4, SCC9 and H357 Cell
Tested Concentrations: 0-30 μM
Incubation Duration: 48 hrs (hours)
Experimental Results: Inhibitory effect on H357, SCC4 and SCC9 cells, IC50 are 2.6, 7.1 and 8.1 μM respectively . The normal HOK cell line did not show any cell death effect. Cell proliferation experiment [4]
Cell Types: H357
Tested Concentrations: 0.5, 1.0, 1.5, 2.0 and 2.5 μM
Incubation Duration: 0, 8 and 16 h
Experimental Results: Proliferation was inhibited.
Western Blot Analysis[4]
Cell Types: H357
Tested Concentrations: 1, 2.5 and 5 μM
Incubation Duration: 48 hrs (hours)
Experimental Results: DDX3 protein expression levels were Dramatically diminished, but not completely eliminated, compared to DMSO-treated cells. Upregulates the expression of E-cadherin.
Apoptosis analysis[4]
Cell Types: H357
Tested Concentrations: 2.5 and 5 μM
Incubation Duration: 48 hrs (hours)
Experimental Results: Induction of apoptosis.
For cell-based assays, LPS-stimulated macrophages or IL-1β-stimulated cells are treated with ketorolac hemicalcium (0.1 nM–10 μM), and PGE2 in culture supernatants is measured by ELISA. Cell viability is assessed by MTT.
Animal Protocol
Animal/Disease Models: New Zealand white rabbit (2.0–2.7 kg), ocular inflammation caused by LPS endotoxin [1]
Doses: 50 μL ketorolac trometamol eye drops 0.4%
Route of Administration: two times before LPS challenge, 2 hour and 1 hour intraocular
Experimental Results: Almost complete inhibition (98.7%) of LPS endotoxin-induced increase in anterior chamber FITC (fluorescein isothiocyanate)-dextran and resulted in almost complete inhibition (97.5%) of LPS endotoxin Induced aqueous phase PGE2 concentration increases in aqueous humor.
Animal/Disease Models: Male Wistar rat (400-450 g), spinal cord ischemia model [3]
Doses: 30 and 60 μg
Route of Administration: intrathecal injection, once 1 hour before ischemia induction
Experimental Results:Dramatically alleviated movement disorders , the rate of improving survival rate is 60 μg.
Animal/Disease Models: balb/c (Bagg ALBino) mouse, oral carcinogenesis model [4]
Doses: 20 mg/kg and 30 mg/kg
Route of Administration: IP injection, twice a week for 3 weeks
Experimental Results: Tumor load reduction, DDX3 and anti- diminished exp
For in vivo studies, rats or mice with carrageenan-induced paw edema or postoperative pain receive ketorolac hemicalcium (e.g., 1–10 mg/kg, oral or i.p.), and paw volume or pain behaviors are measured. Plasma drug concentrations are quantified by LC-MS/MS.
References
[1]. Waterbury LD, et al. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
[2]. Fracon RN, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats. J Appl Oral Sci. 2010 Dec;18(6):630-4.
[3]. Hsieh YC, et al. Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats. Anesth Analg. 2005 Apr;100(4):1134-9.
[4]. Samal SK, et al. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. Sci Rep. 2015 Apr 28;5:9982.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C30H24CAN2O6
Molecular Weight
548.599367141724
Exact Mass
548.126
CAS #
167105-81-9
Related CAS #
Ketorolac;74103-06-3;(S)-Ketorolac;66635-92-5;(R)-Ketorolac;66635-93-6;Ketorolac-d5;1215767-66-0
PubChem CID
71587565
Appearance
White to off-white solid
LogP
1.912
tPSA
124.26
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
6
Rotatable Bond Count
4
Heavy Atom Count
39
Complexity
370
Defined Atom Stereocenter Count
0
SMILES
[Ca+2].[O-]C(C1C2=CC=C(C(C3C=CC=CC=3)=O)N2CC1)=O.[O-]C(C1C2=CC=C(C(C3C=CC=CC=3)=O)N2CC1)=O
InChi Key
NPCGTDZMTWNBDA-UHFFFAOYSA-L
InChi Code
InChI=1S/2C15H13NO3.Ca/c2*17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;/h2*1-7,11H,8-9H2,(H,18,19);/q;;+2/p-2
Chemical Name
calcium;5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~14.3 mg/mL (~52.1 mM; with ultrasonication and adjustment of pH to 3 with 1 M HCl and heat to 60°C)
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.8228 mL 9.1141 mL 18.2282 mL
5 mM 0.3646 mL 1.8228 mL 3.6456 mL
10 mM 0.1823 mL 0.9114 mL 1.8228 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration: mg/mL;

Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Contact Us